Ensysce Biosciences (ENSCW) FCF Margin (2020 - 2025)
Ensysce Biosciences (ENSCW) reported FCF Margin of 378.46% for Q3 2025, down 34861.0% year-over-year from N/an in Q3 2024, and down 91.74% quarter-over-quarter from 197.37% in Q2 2025.
Ensysce Biosciences (ENSCW) FCF Margin (2020 - 2025) Analysis & Trends
Ensysce Biosciences (ENSCW) has 6 years of FCF Margin data on file, last reported at 378.46% in Q3 2025.
- FCF Margin for Q3 2025 came in at 378.46%, down 34861.0% year-over-year; the trailing twelve-month figure through Sep 2025 was 156.97% (up 3620.0% YoY), and the FY2024 annual result was 144.0%, up 33929.0% from the prior year.
- FCF Margin fell to 378.46% in Q3 2025 per ENSCW's latest filing, from 197.37% in the prior quarter.
- Over five years, FCF Margin peaked at 29.77% in Q2 2021 and troughed at 2403.54% in Q3 2022.
- A 5-year average of 593.05% and a median of 349.86% in 2023 frame the typical range for FCF Margin.
- The sharpest annual moves came in 2022 and 2023: FCF Margin slumped 211053 bps in 2022, then soared 188384 bps in 2023.
- A 5-year view of FCF Margin shows it stood at 230.41% in 2021, then climbed by 0 bps to 229.91% in 2022, then slumped by 52 bps to 349.86% in 2023, then jumped by 83 bps to 58.61% in 2024, then tumbled by 546 bps to 378.46% in 2025.
- Business Quant data shows ENSCW's FCF Margin at 378.46% in Q3 2025, 197.37% in Q2 2025, and 129.37% in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -3.98% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 43.35% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Ensysce Biosciences | - | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -378.46% |
| Jun 30, 2025 | -197.37% |
| Mar 31, 2025 | -129.37% |
| Dec 31, 2024 | -58.61% |
| Sep 30, 2024 | -29.84% |
| Jun 30, 2024 | -1,270.59% |
| Mar 31, 2024 | -1,114.87% |
| Dec 31, 2023 | -349.86% |
| Sep 30, 2023 | -519.69% |
| Jun 30, 2023 | -633.79% |
| Mar 31, 2023 | -456.78% |
| Dec 31, 2022 | -229.91% |
| Sep 30, 2022 | -2,403.54% |
| Jun 30, 2022 | -2,140.30% |
| Mar 31, 2022 | -569.89% |
| Dec 31, 2021 | -230.41% |
| Sep 30, 2021 | -318.53% |
| Jun 30, 2021 | -29.77% |
| Mar 31, 2021 | -206.38% |
| Dec 31, 2020 | -128.18% |